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It is likely that human genetic differences mediate susceptibility to viral infection and virus-triggered disorders.
OAS genes encoding the antiviral enzyme 2′,5′-oligoadenylate synthetase (2′5′AS) are critical components of the
innate immune response to viruses. This enzyme uses adenosine triphosphate in 2′-specific nucleotidyl transfer
reactions to synthesize 2′,5′-oligoadenylates, which activate latent ribonuclease, resulting in degradation of viral
RNA and inhibition of virus replication. We showed elsewhere that constitutive (basal) activity of 2′5′AS is correlated
with virus-stimulated activity. In the present study, we asked whether constitutive activity is genetically determined
and, if so, by which variants. Analysis of 83 families containing two parents and two children demonstrated
significant correlations between basal activity in parent-child pairs ( ) and sibling pairs ( ), butP ! .0001 Pp .0044
not spousal pairs, suggesting strong genetic control of basal activity. We next analyzed association between basal
activity and 15 markers across the OAS gene cluster. Significant association was detected at multiple markers, the
strongest being at an A/G single-nucleotide polymorphism at the exon 7 splice-acceptor site (AG or AA) of the
OAS1 gene. At this unusual polymorphism, allele G had a higher gene frequency in persons with high enzyme
activity than in those with low enzyme activity (0.44 vs. 0.20; ). Enzyme activity varied in a dose-511Pp 3# 10
dependent manner across the GG, GA, and AA genotypes (tested by analysis of variance; ). Allele514Pp 1# 10
G generates the previously described p46 enzyme isoform, whereas allele A ablates the splice site and generates a
dual-function antiviral/proapoptotic p48 isoform and a novel p52 isoform. This genetic polymorphism makes
OAS1 an excellent candidate for a human gene that influences host susceptibility to viral infection.
Introduction
Although viral diseases have undoubtedly been major fac-
tors in human evolution, both past and present (e.g., in-
fluenza and HIV), there have been relatively few studies
aimed at identifying the human genetic differences that
influence susceptibility/resistance to viral infection. After
exposure to novel viruses, interferon-a is one of the first
cytokines released from immune-competent cells, initiat-
ing an innate antiviral response via induction of numerous
interferon-stimulated genes (Der et al. 1998; Levy and
Garcia-Sastre 2001; Sen 2001). Among these are the OAS
genes, which encode the critical effector enzyme 2′,5′-oli-
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goadenylate synthetase (2′5′AS); 2′5′AS requires double-
stranded (ds) RNA structures, such as viral genomes, to
become activated. The activated enzyme then catalyzes
the polymerization of ATP into 2′,5′-linked oligoadeny-
lates (2′5′A), and these, in turn, bind to and activate latent
ribonuclease (RNaseL), which degrades viral as well as
cellular RNA and inhibits protein synthesis. Recently,
amino acid sequences of 2′5′AS required for dsRNA bind-
ing have been identified through crystallography and
structure-guided mutagenesis (Hartmann et al. 2003),
and evolutionary conservation analysis has suggested that
these sequences may also have nuclease function (Rogozin
et al. 2003). The 2′5′AS-RNaseL system may also be in-
volved in growth and apoptosis; for example, several stud-
ies have implicated genetic variation at the RNASEL locus
(MIM 180435) in susceptibility to prostate cancer (re-
viewed by Silverman [2003]), possibly through the dif-
ferential effects of such genetic variants on RNaseL en-
zyme activity (Casey et al. 2002; Xiang et al. 2003).
2′5′AS is actually a family of enzymes encoded by three
closely linked genes on human chromosome 12q24.2,
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with the following order: OAS1 (MIM 164350), encod-
ing the p42, p44, p46, and p48 isoforms; OAS3 (MIM
603351), encoding p100; and OAS2 (MIM 603350), en-
coding p69 and p71 (reviewed by Justesen et al. [2000]).
In the mouse, the importance of 2′5′AS for clearing viral
infections was recently demonstrated by studies showing
that host susceptibility to West Nile virus (WNV) and
other flaviviruses is controlled by the Oas1b gene, the
mouse homologue of OAS1. Mouse strains with an exon
4 point mutation resulting in truncation of the L1 isoform
showed 100% mortality after WNV infection, whereas
strains lacking this mutation showed restricted virus rep-
lication and no mortality (Mashimo et al. 2002; Perelygin
et al. 2002). Similarly, in vitro studies demonstrated that
WNV replication was less efficient in mouse neuroblas-
toma cell lines expressing the wild-type Oas1b gene, com-
pared with cells expressing the mutant gene (Lucas et
al. 2003). In humans, we have shown that constitutive
(basal) activity of 2′5′AS varies among individuals and is
associated with susceptibility to type 1 diabetes (Bon-
nevie-Nielsen et al. 2000), an autoimmune disorder
whose etiopathogenesis is thought to involve enterovirus
infections (see the studies by Hyo¨ty et al. [1995], Hil-
tunen et al. [1997], Roivainen et al. [1998], and Lo¨nnrot
et al. [2000]). New analysis of data from our earlier study
of human 2′5′AS response to yellow fever vaccine (Bon-
nevie-Nielsen et al. 1989) revealed a highly significant
correlation between basal enzyme activity and virus-stim-
ulated activity measured 7 d after vaccination (65 sub-
jects; correlation coefficient 0.65; ). Thus, anyP ! .0001
genetic variants that affect 2′5′AS activity could be im-
portant determinants of susceptibility/resistance to viral
infection and to virus-related diseases. Human genetic
variation at another innate immune-system gene, man-
nose-binding lectin (MBL), has been reported to be as-
sociated with basal serum MBL levels and immune re-
sponse to a variety of pathogens, including HIV and
hepatitis viruses (Garred et al. 1997; Yuen et al. 1999;
Crosdale et al. 2000; Minchinton et al. 2002). In the
present study, we therefore sought to determine, by fam-
ily studies, whether basal 2′5′AS activity is genetically
controlled and, if so, whether the relevant variants reside
at the OAS gene cluster.
Material and Methods
Subjects
Danish nuclear families ( ) with two parentsnp 83
and two children (n p 332 subjects total) were ascer-
tained at the Diabetes Clinic of Odense University Hos-
pital in Odense, Denmark. In each family, one child had
type 1 diabetes. Blood was taken from all family mem-
bers after completion of informed-consent procedures
that were approved by Odense University and the Uni-
versity of Calgary (previous appointments of V.B.-N.
and L.L.F., respectively), as well as by the University of
British Columbia. Peripheral lymphocyte lysates and ex-
tracted DNA samples were transported by courier to
Canada for analysis.
Marker Genotyping
All genotyped markers exist in public databases (Na-
tional Center for Biotechnology Information, Genome
Database, and Applied Biosystems [ABI]/Celera), al-
though, when selected for analysis, several SNPs were
unvalidated and lacked allele-frequency information. Mi-
crosatellites were genotyped on LI-COR 4200S DNA se-
quencers after PCR amplification by use of publicly avail-
able primer sequences. SNPs were genotyped on an ABI
7000 real-time thermocycler with the use of TaqMan
probes and primers purchased from ABI. SNP probes and
primers were designed using the ABI Assays-by-Design
service (or, in the case of the Celera SNP hCV2567433,
using the ABI Assays-on-Demand service, in which probe
and primer information is not released to the public). The
genomic locations of the typed markers are shown in
figure 1, and the sequences of PCR primers and probes
used for genotyping these markers (or, for hCV2567433,
the genomic sequence including the SNP) are given in table
A1 (online only).
DNA Sequencing and mRNA Analysis
Genomic DNA from 10 unrelated children (5 with
high enzyme activity and 5 with low enzyme activity)
was sequenced for all seven exons (including UTRs),
flanking intronic sequences, and regulatory regions of
OAS1 (primer sequences are provided in table A2 [online
only]). Sequencing was performed by the Core Sequenc-
ing Laboratory of the Canadian Genetic Diseases Net-
work of Centres of Excellence in Vancouver, by use of
direct sequencing methods, on an ABI 3100 Genetic An-
alyzer (BigDye Terminator Cycle Sequencing Kit, version
3.1). Multiple sequences were aligned with ClustalW
software (see the ClustalW Web site) to identify sequence
variants. The results of sequencing exon 7 and flanking
regions in the 10 unrelated persons are given in table
A3 (online only).
Fresh lymphocytes from healthy individuals (two with
genotype AA and one with genotype GA) and lymphoid
Daudi cells (with genotype GG) were used for OAS1
mRNA analysis. Primers for RT-PCR amplification of
cDNA from p46 and p48 mRNA were positioned in
exon 5 and in exon 7, downstream of the p48 splice-
acceptor site (primer sequences are given in appendix A
[online only]). These primers were designed to yield 417-
bp and 319-bp fragments for the p46 and p48 splice
variants, respectively, which were separated on 2% aga-
rose gel, stained with ethidium bromide, and detected
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Figure 1 Schematic map showing the genomic positions of the genetic markers typed
under UV light (fig. 2). Both nonstimulated and inter-
feron-a–stimulated cells were employed, with qualita-
tively similar results. The existence of mRNA for the
novel p52 variant was determined by excision and se-
quencing of the upper band in the two persons with the
AA genotype. The identities of the p46 and p48 bands
were confirmed by sequencing cDNA from the excised
417-bp band in the person with the GG genotype and
from the 319-bp band in the two persons with the AA
genotype, respectively.
Measurement of 2′5′AS Enzyme Activity
Basal (constitutive) 2′5′AS activity was assayed in lys-
ates prepared from peripheral blood lymphocytes by
measurement of the rate of conversion of radiolabeled
ATP to 2′5′A, as described elsewhere (Bonnevie-Nielsen
et al. 2000). Radioactive 32P-ATP was added to a re-
action mixture containing an ATP-generating system
(creatine kinase plus creatine phosphate) to ensure con-
stant molarity of ATP during incubation. Sample protein
was adjusted to a concentration optimal for the enzyme’s
conversion of ATP. Samples containing generated 2′5′A
were spotted on polyethylene-imine (PEI) plates, sepa-
rated overnight by ascending thin-layer chromatography
(TLC), and autoradiographed for detection. The radio-
active ATP and generated 2′5′A spots were cut from the
TLC plate and quantitated in a b-scintillation counter.
Enzyme activity is expressed in units per mg protein,
with “1 unit” defined as nanomoles of ATP converted
to 2′5′A per minute. Samples were assayed in duplicate.
The analytical variance (SD) of the assay was calculated
to be 36% from internal-control samples of baculovirus-
expressed 2′5′AS (p46).
Statistical Analyses
The enzyme activities among the 332 subjects ranged
from 1.30 U/mg to 21.78 U/mg, with a mean  SD of
. Prior to data analysis, four outliers with3.79 2.19
enzyme activities 13 SD above the mean (a father and
three children from four different families, with enzyme
activities of 19.82, 11.14, 17.26, and 21.78) were ex-
cluded from all analyses involving enzyme activity, since
such extreme activity measures might reflect an ongoing
response to virus exposure rather than constitutive lev-
els. (The 2′5′AS activity observed after viral infection or
stimulation with polyI:C, a synthetic dsRNA, is typically
5–10 times higher than the basal activity.) Among the
remaining 328 subjects, enzyme activities ranged from
1.30 U/mg to 9.90 U/mg, with a mean  SD of
. One additional child who was assayed for3.62 1.52
enzyme activity was included in the activity correlation
analyses but was excluded from the activity by marker
association analyses because no DNA sample was avail-
able for marker genotyping. Diabetes status in the chil-
dren was ignored in all analyses.
The Statistical Analysis System (SAS) software package
was used to calculate correlations of enzyme activity be-
tween relative pairs, P values associated with the corre-
lation coefficients, analysis of variance (ANOVA) of en-
zyme activity versus OAS1 splice-site genotypes, and the
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Figure 2 Expression of OAS1 p46, p48, and p52 in interferon-
a–stimulated human cells. M p molecular-weight standard. Lane 1,
AA genotype; lane 2, GA genotype; and lane 3, GG genotype. RT-
PCR primers were designed to amplify cDNA segments of sizes 417
bp and 319 bp, corresponding to the p46 and p48 splice variants,
respectively. Unexpectedly, the primers also amplified a 416-bp seg-
ment, corresponding to a novel p52 variant (see text). Results produced
by use of nonstimulated cells were qualitatively similar, but bands were
fainter.
P value associated with the ANOVA statistic. To analyze
association between genetic marker-allele frequencies and
enzyme activity, all 327 subjects were categorized as be-
longing to either “high-activity” or “low-activity” groups,
which were defined by the median cutoff value of 3.33,
resulting in 164 persons assigned to the high-activity
group and 163 persons assigned to the low-activity group.
The significance of differences in genetic marker-allele fre-
quencies between these two groups was then analyzed by
x2 testing with a contingency table. For microsat-2# 2
ellite markers, the most common (major) allele was com-
pared with the sum of all other alleles. Similar proce-
dures were used to analyze the effects of markers while
controlling for genetic variation at the splice-site SNP
hCV2567433. For example, to test for association be-
tween enzyme activity and rs3741981 in the subset of
subjects who had splice-site genotype AA, the median
enzyme activity value in that subset was used to create
high- and low-activity groups, and then rs371981 allele
frequencies in the two groups were compared.
Results and Discussion
Analysis of basal 2′5′AS activity in members of 83 Danish
families showed highly significant correlations between
genetically related individuals, but not between spouses.
Correlation coefficients were 0.33 for mother-child pairs
( ), 0.36 for father-child pairs ( ), andP ! .0001 P ! .0001
0.32 for sibling pairs ( ) but were 0.14 forPp .0044
parental pairs ( [not significant]). A completelyP 1 .05
genetic quantitative trait would show correlation coef-
ficients of 0.5 for relative pairs who share 50% of their
genes (i.e., parent-child or sibling pairs) and no cor-
relation between genetically unrelated spouses. Thus, the
results suggest that basal 2′5′AS activity is under strong
genetic control.
To determine whether the genetic variants controlling
2′5′AS activity were located in the OAS gene cluster, we
genotyped the SNP rs3741981 in OAS1, the microsat-
ellite D12S2397 located between OAS3 and OAS2, and
the SNP rs2240185 in OAS2. Association with 2′5′AS
activity was analyzed by classifying all subjects as hav-
ing either high or low enzyme activity and then com-
paring marker-allele frequencies in these two groups (for
more details, see the “Material and Methods” section).
Results showed highly significant associations between
enzyme activity and all three OAS-region markers. We
therefore genotyped an additional 12 markers across
and flanking the OAS gene cluster and found that the
strongest associations were with markers in OAS1 (see
table 1). To identify all other polymorphic OAS1 var-
iants, we sequenced all seven OAS1 exons, including
UTRs, flanking intronic sequences, and the 5′ regulatory
region in 10 unrelated individuals (5 with high enzyme
activity and 5 with low enzyme activity). Sequencing
identified only one additional (previously known) SNP
in exon 7, which was then typed in all subjects. Thus,
no new OAS1 polymorphisms were found by sequenc-
ing. Figure 1 shows the locations of genotyped markers,
and table A3 (online only) gives the exon 7 genomic
sequences of the 10 persons.
The results presented in table 1, which suggested that
genetic markers in OAS1 were the most strongly asso-
ciated with enzyme activity, were derived by analyzing
gene frequencies in two artificial “high enzyme activity”
and “low enzyme activity” groups. To attempt to confirm
these results by use of a different method, we analyzed
the variance in enzyme activity across groups defined by
marker genotype. Table 2 shows the ANOVA results for
all markers that produced significant differences between
the high- and low-activity groups in table 1. These
ANOVA results also suggested that the markers most
strongly associated with enzyme activity were OAS1
markers.
The strongest genetic association with 2′5′AS activity,
both by analysis of gene frequencies in enzyme activity
groups (table 1) and by analysis of enzyme activity in
genotype groups (table 2), occurred at SNP marker
hCV2567433, whose G and A alleles govern splicing to
the last OAS1 exon (exon 7), and at a block of three
other markers downstream within exon 7 (rs3177979,
rs1051042, and rs2660) (see bold italics in tables 1 and
2). These four SNPs were in virtually complete linkage
disequilibrium, such that (with one exception) only two
haplotypes were found among 332 parental chromo-
somes: G-G-G-G, with an overall frequency of 0.32,
and A-A-C-A, with a frequency of 0.68. The one ex-
ception was a single G-A-C-A haplotype found in one
parent and transmitted to both children (thus, this rare
haplotype has an estimated frequency of 0.3%).
The sequence AG is required for normal splicing at
splice-acceptor sites. The G allele at SNP hCV2567433
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Table 2
ANOVA for Enzyme Activity in Subjects Categorized by Genetic Marker Genotype
MARKER (12cenrqter)
MEAN ENZYME ACTIVITY  SD (GENOTYPE)
F P
Lower-Activity
Genotype
Intermediate-Activity
Genotype
Higher-Activity
Genotype
rs3741981 2.97  1.05 (AA) 3.88  1.55 (GA) 4.28  1.85 (GG) 19.4 1 # 108
hCV2567433a 2.96  1.00 (AA) 4.02  1.56 (GA) 4.87  1.98 (GG) 35.5 1 # 1014
rs3177979 2.97  1.00 (AA) 4.03  1.56 (GA) 4.85  2.02 (GG) 34.5 3 # 1014
rs1051042 2.97  1.00 (CC) 4.03  1.56 (GC) 4.85  2.02 (GG) 34.5 3 # 1014
rs2660 2.97  1.00 (AA) 4.03  1.56 (GA) 4.85  2.02 (GG) 34.5 3 # 1014
D12S2397 3.04  1.09 (X/X) 3.71  1.50 (X/236) 4.11  1.73 (236/236) 11.9 1 # 105
rs2072138 3.03  .88 (GG) 3.50  1.56 (CG) 3.88  1.58 (CC) 6.0 3 # 103
rs2072137 3.26  1.23 (CC) 3.42  1.37 (TC) 4.25  1.79 (TT) 12.2 8 # 106
rs2240185 3.19  1.22 (GG) 3.50  1.35 (GC) 4.34  1.88 (CC) 14.0 1 # 106
rs1293739 3.09  .99 (AA) 3.51  1.49 (GA) 3.74  1.57 (GG) 2.0 .14
NOTE.—Findings for haplotype block markers are in bold italics. “X” represents any allele other than 236 bp.
a Celera ID.
(AG at acceptor site) retains the splice site and is asso-
ciated with high enzyme activity, whereas the more com-
mon A allele (AA at acceptor site) ablates the splice site
and is associated with low enzyme activity. The frequency
of the G allele was 0.199 in the low-activity group, com-
pared with 0.442 in the high-activity group (Pp 3#
) (table 1). The G-allele frequency difference was1110
even larger between the lowest and highest 25% of the
enzyme activity distribution: 0.152 versus 0.512 (Pp
). Analysis of enzyme activities for the three124# 10
splice-site genotypes revealed a dose-dependent effect (ta-
ble 2). Among 147 individuals with genotype AA, 150
individuals with genotype GA, and 30 individuals with
genotype GG, the mean (U/mg) SD of the enzyme ac-
tivity was , , and ,2.96 1.00 4.02 1.56 4.87 1.98
respectively, a highly significant progression (ANOVA
) (table 2). In summary, the more G alleles14Pp 1# 10
that a person has at the splice-acceptor site, the higher
the person’s basal 2′5′AS activity.
In the above analyses, we included all 327 subjects
to maximize sample size. The use of related subjects is
not expected to increase the chance of false-positive re-
sults, since all families are of identical structure (two
parents and two children) and therefore receive equal
weight. To confirm that this is the case, we tested for
association between enzyme activity and splice-site ge-
notype with the use of only the 165 unrelated parents.
Results for both analysis methods showed a highly sig-
nificant association: (1) in analysis of allele frequencies,
the G-allele frequencies in the low- and high-activity
groups were essentially identical to those observed with
the use of all subjects (0.201 in the low-activity group,
compared with 0.434 in the high-activity group; 2x p
; ), and, (2) in analysis of enzyme620.56 Pp 6# 10
activity variance across splice-site genotypes, a highly
significant relationship was also demonstrated (ANOVA
; ).6Fp 14.6 Pp 2# 10
The significant associations between enzyme activity
and other OAS markers could be independent effects or
could be merely secondary to linkage disequilibrium be-
tween the splice-site variants and the other markers. To
discriminate between these two possibilities, we tested
for association with the other markers (except the three
markers in the exon 7 haplotype block discussed above)
while fixing genetic variation at the splice site. When
analysis was restricted to individuals with splice-site ge-
notype AA, no association was detected between enzyme
activity and any of the other markers that showed sig-
nificant results in table 1 (i.e., rs3741981, D12S2397,
rs2072138, rs2072137, rs2240185, and rs1293739).
Similarly, no significant associations were found with
other markers when analysis was restricted to individuals
with splice-site genotype GA. For example, table 3 pres-
ents the results of testing for association with rs3741981
(the second most strongly associated marker in the total
data set) while fixing variation at the splice-site SNP.
These results indicate no relation between rs3741981 and
enzyme activity when the effects of variation at the splice
site were removed. However, table 4 shows that, when
the reverse procedure was performed by testing for as-
sociation with the splice-site SNP while fixing variation
at rs3741981, significant effects of the splice-site variants
were still detectable (with an increased frequency of the
G allele in the high-activity group). Similar results were
obtained for other markers. For example, there was no
significant association between D12S2397 and enzyme
activity when variation at the splice-site SNP was fixed,
but, when the reverse procedure was performed by con-
sidering only persons with the most common genotype
236/236 at D12S2397, a significant increase of the splice-
site G allele was seen in persons with high enzyme activity
versus those with low enzyme activity (0.65 vs. 0.47;
). Finally, it is theoretically possible that thePp .024
association of the splice-site polymorphism with enzyme
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Table 3
Association of rs3741981 with Enzyme Activity (with Variation Fixed at the Splice-Site SNP)
rs3741981
ALLELE
rs3741981 ALLELE COUNT (FREQUENCY) FOR
Individuals with Splice-Site
Genotype AAa
Individuals with Splice-Site
Genotype GAa
Individuals with Splice-Site
Genotype GGb
Low-Activity
Group
High-Activity
Group
Low-Activity
Group
High-Activity
Group
Low-Activity
Group
High-Activity
Group
A 127 132 66 69 0 0
G 19 (.13) 16 (.11) 84 (.56) 81 (.54) 30 (1.0) 30 (1.0)
Total 146 148 150 166 30 30
a P value for the low-activity group versus the high-activity group was not significant.
b No variation between the low-activity group and the high-activity group.
Table 4
Association of Splice-Site SNP with Enzyme Activity (with Variation Fixed at rs3741981)
SPLICE-SITE
ALLELE
SPLICE-SITE ALLELE COUNT (FREQUENCY) FOR
Individuals with rs3741981
Genotype AAa
Individuals with rs3741981
Genotype GAb
Individuals with rs3741981
Genotype GGc
Low-Activity
Group
High-Activity
Group
Low-Activity
Group
High-Activity
Group
Low-Activity
Group
High-Activity
Group
A 114 116 104 89 16 5
G 0 (.0) 0 (.0) 58 (.36) 77 (.46) 32 (.67) 43 (.90)
Total 114 116 162 166 48 48
a No variation between the low-activity group and the high-activity group.
b for the low-activity group versus the high-activity group.Pp .052
c for the low-activity group versus the high-activity group.Pp .007
activity could be secondary to one of the three SNPs in
almost complete linkage disequilibrium with the splice-
site SNP (indicated by the bold italics that designate the
haplotype block markers in tables 1 and 2). It is impos-
sible to test this by use of the type of restricted analysis
performed above for other associated markers. However,
as will be shown below, the magnitude of the protein
structural change due to the splice-site polymorphism is
much greater than that due to the remaining three SNPs.
Together, these results strongly suggest that the primary
association of enzyme activity is with the splice-site poly-
morphism (i.e., the splice-site SNP is the causal variant)
and that the associations observed with other OAS mark-
ers are secondary to linkage disequilibrium between the
splice-site variants and those other markers (although the
possibility of minor effects due to other variants cannot
be ruled out).
Since the A allele ablates the splice-acceptor site, we
next asked whether splicing to exon 7 occurs in mRNA
transcripts derived from A-allele sequences and, if so,
which splice site is used. Ghosh et al. (2001) reported
elsewhere that exon 7 splicing can occur both at an
upstream site, producing the p46 isoform, and—ap-
parently by classical alternative splicing of the same
transcript—further downstream, producing the p48 iso-
form. (Note that lack of exon 7 splicing results in the
smaller p42 isoform [see footnote a in table 1].) Because
splicing at the more downstream site causes a reading-
frame change, the p46 and p48 isoforms have different
amino acid sequences at their carboxyl-terminal tails.
In the present study, we have shown that, since the
upstream site is genetically variable, only the G allele
can generate p46. To determine whether A-allele tran-
scripts use the downstream p48 splice site, we amplified
mRNA from persons with AA, GA, and GG genotypes
by use of primers designed to amplify 417-bp and 319-
bp segments from p46 and p48 mRNAs, respectively.
Figure 2 shows that genotypes AA and GA, but not GG,
have the lower band corresponding to p48 splicing, sug-
gesting that only the A allele generates p48 (although
more individuals with the GG genotype need to be tested
to verify this). Unexpectedly, all three genotypes showed
the upper band corresponding to p46 (G allele) splicing.
However, DNA sequencing of this band from the two
individuals with the AA genotype revealed that the ac-
tual size was 416 bp, rather than 417 bp—splicing had
occurred at the next AG sequence, located only one base
downstream of the splice-site polymorphism (see fig. 3).
Splicing at this single-base–shifted position alters the
reading frame, resulting in a large, novel, previously
undescribed 2′5′AS isoform with predicted molecular
weight p52. Figure 2 implies that this shifted A-allele
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Figure 3 Schematic diagram of splicing events generating the p46 and novel p52 cDNA sequences. Exons 5 and 7 (boxes) are spliced
together following the “ag” at the splice-acceptor site. A, Sequence containing a “g” (G allele) at the splice-site SNP (hCV2567433) (vertical
arrow). B, Sequence containing an “a” (A allele) at the SNP, which shifts the splice-acceptor site one base downstream. The resulting splice
variants were determined to have the cDNA sequences shown to the right of the horizontal arrows, with the p46 sequence having an extra G,
compared with the p52 sequence.
splice site is not optimal, since alternative splicing using
the downstream p48 site also occurs in persons with
the AA and GA genotypes. In summary, only persons
possessing at least one G allele can produce the p46
isoform; persons having only A alleles cannot make p46
but can produce other isoforms, such as p48 and p52.
Figure 4 summarizes the splicing events leading to the
p46, p48, and p52 isoforms, as well as the amino acid
sequences translated from each of these exon 7 splice
variants, which result in very diverse protein sequences
for the isoform C-terminal tails.
Our findings suggest that the high-enzyme-activity G
allele produces the p46 isoform, whereas the low-activ-
ity A allele produces the novel p52 isoform as well as
the p48 isoform (by alternative splicing). We surmised
that the HT1080 cell line, which was reported by Ghosh
et al. (2001) to produce mRNAs for both p46 and p48,
came from a person with the GA genotype, and we have
confirmed this by genotyping HT1080 cells. Most in-
terestingly, these investigators showed that the p48 iso-
form has proapoptotic activity, which the investigators
localized to a BH3 (Bcl-2 homology-3) domain encoded
by exon 7. This proapoptotic activity of p48 was inde-
pendent of its synthetase and RNaseL-activating capa-
bilities. It remains to be determined why basal 2′5′AS
activity is higher in persons carrying the G (p46) allele
than in those having only the A (p48/p52) allele. Perhaps
p46 is a more efficient synthetase than p48 and/or p52;
however, this is highly speculative, and there is no evi-
dence that the C-terminal tail is involved in functional
aspects of the 2′5′AS molecule, such as ATP binding,
dsRNA binding (necessary for enzyme activation), or tet-
ramer formation (required for p48 activation [Ghosh et
al. 1997]). It should be noted that other 2′5′AS isoforms
(e.g., OAS1 p42 isoform and OAS2 isoforms) most likely
also contribute to total basal 2′5′AS activity; however, the
present study suggests that interindividual differences in
total enzyme activity result primarily from genetically
determined splice variants of OAS1.
Examples exist of rare splice-site mutations causing
genetic disease as a consequence of impaired or absent
functioning of the resultant protein. However, to our
knowledge, this is the first example of a common splice-
site polymorphism (both alleles abundant in the general
population) that generates different functional proteins
that may have differential effects on predisposition to
common diseases. The three genotypes AA, GA, and GG
show systematic variation in basal 2′5′AS antiviral en-
zyme activity. A recent study reported that European
patients with persistent hepatitis C virus infection had
a significantly higher frequency of genotype GG at OAS1
SNP rs2660, which we have shown above to be almost
perfectly correlated with genotype GG at the splice-site
polymorphism, compared with patients with self-limiting
hepatitis C infection (Knapp et al. 2003). By inference,
patients with persistent infection also had increased fre-
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Figure 4 Schematic diagram of the DNA sequences, splicing events, and translated proteins for the p46, p48, and p52 isoforms. A, p46,
generated from the G allele at the splice-acceptor site SNP (hCV2567433). B, p52 and p48, generated from the A allele at splice-site SNP. C,
Exon 7 translated amino acid sequences for p46, p48, and p52. SNPs rs3177979, rs1051042, and rs2660 are within codons of the underlined
amino acids. For p46, rs2660 is untranslated; the splice-site G allele is in linkage disequilibrium with allele G at rs3177979 and allele G at
rs1051042, producing amino acids A (GCA) and R (AGG), respectively. For p48, rs3177979 and rs1051042 are untranslated; splice-site allele
A is in disequilibrium with allele A at rs2660, producing amino acid R (AGA). For p52, splice-site allele A is in disequilibrium with alleles A,
C, and A at the three SNPs, producing amino acids V (GTA), R (CGT), and K (AAG), respectively.
quencies of genotype GG at the splice-site polymorphism
that (paradoxically) is associated with high basal antiviral
enzyme activity. Similarly, we have evidence that patients
with type 1 diabetes have higher basal 2′5′AS activity
(Bonnevie-Nielsen et al. 2000) and significantly higher
frequencies of splice-site genotypes GG and GA than con-
trol subjects (Field et al., in press). To reconcile this ap-
parent paradox, we hypothesize that persons with GG
and GA genotypes, despite having higher basal 2′5′AS
activity than persons with AA, are unable or less able to
mount an important antiviral response through the (non-
2′5′AS–RNaseL) p48 proapoptotic pathway. Clearly, fur-
ther studies are needed to determine the precise relation-
ship between p46/p48/p52 isozymes, 2′5′AS antiviral/
apoptotic activities, and the degree to which the OAS1
splice-site genotypes predict variation in immune re-
sponse to important viral pathogens and variation in cel-
lular apoptotic parameters.
In this Danish sample, the G-allele frequency was 0.32,
similar to that found in 99 unrelated Danes (0.34) (L.L.F.,
F.P., and V.B.-N., unpublished data) and to that reported
in the ABI/Celera database for European-originating peo-
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ple (0.35). In contrast, the G-allele frequency for 45 Af-
rican Americans in the ABI/Celera database is higher
(0.47) and for 288 healthy Hong Kong Chinese is lower
(0.24) (L.L.F., Y.-L.L., and V.B.-N., unpublished data).
Hong Kong Chinese subjects also demonstrate very
strong disequilibrium between the splice-site polymor-
phism and rs2660, with the same two common haplo-
types (G-G and A-A) as were found in Danes in the
present study. The G variant at the splice site is ancient
and possibly “ancestral,” since the recently released se-
quence of our closest relative, the chimpanzee Pan trog-
lodytes, displays a G allele (both at the splice site and at
rs2660) (see the UCSC Genome Browser). Thus, the fre-
quency of the common A allele at the splice site could
vary significantly across human populations, perhaps as
a result of differences in their virus-exposure history and
concomitant natural selection.
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